Invasive fungal infections (IFIs) are one of the most significant public health challenges worldwide. Yet, research and communication thereof were left behind for a long time, until the WHO published a priority pathogens list to guide research, development, and public health action in October 2022. Indeed, due to the rising number of immunocompromised patients at risk and the high level of morbidity, mortality, and economic burden they entail, especially in low- and middle-income countries, IFIs are a serious public health threat. Fungal infections due to dimorphic fungi face additional challenges such as limited knowledge outside of endemic areas and restricted availability of antifungal molecules in areas affected by these infections. The number of related deaths per year is estimated at 2.5 million, but non-governmental organisations make a wider estimation, due to the difficulties in early in vitro diagnostic and troublesome collection and analysis of epidemiological data. Despite this fact, the therapeutic toolbox addressing these infections remains limited, with only four main families of molecules available so far. The antifungal therapeutic supply is composed of very toxic polyenes, the weakly selective and nearly unused 5-fluorocytosine, and azoles, some of which are becoming increasingly inefficient against IFIs. In the 2000–2020s, the fourth arising family consisted of safer semisynthetic echinocandins. Unfortunately, nowadays, more and more fungal isolates encountered in intensive care units exhibit a low susceptibility to echinocandins or are even multiresistant. In this review, we expose the current treatments available to fight against invasive fungal infections. We recall the discovery and physico-chemical aspects of these substances leading to structure/activity and structure/properties relationships. We particularly focus on the to-date resistances and their molecular mechanisms. We finally list some of the most relevant antifungal drug candidates, as they were freshly overviewed by the World Health Organization in April 2025, highlighting the importance of the molecular dimension of this pursuit toward the expansion of the antifungal therapeutic toolbox.
Before the 2000s, the antifungal toolbox against invasive fungal infections (IFIs) was only composed of very toxic amphotericin B, weakly selective and nearly unused 5-fluorocytosine and azoles that have been massively used in agriculture and horticulture. The emergence of resistances followed their respective launch, so many antifungals became progressively inefficient whereas the antifungal research was left behind. In the 2000s, echinocandins (ECs) were introduced as a new antifungal class of natural origin and of unprecedented mechanism of action. ECs, especially first-in-class caspofungin, are reputed to inhibit β-(1,3)-D-glucan synthase, an enzyme involved in the biosynthesis of the fungal cell wall. Their lipocyclohexapeptidic semisynthetic nature and their original mechanism of action made them reliable therapeutic agents for the treatment of fungal nosocomial infections. Advantageously, their weak hepatic metabolism and slow elimination limit drug-drug interactions in polymedicated patients or those with liver or renal dysfunctions. After a general introduction, here we report historical facts about ECs' discovery and development. The ECs' mechanism of action is then tackled under the structural angle, enlightening the importance of recent results from chemical biology and molecular modelling approaches in the knowledge of this important therapeutic class. The heart of our work is a comprehensive updated review on structure-activity (SAR) and structure-properties relationships (SPR) related to this family. Finally, resistance data are discussed and presented in tables to facilitate their consulting. We finally list the most relevant antifungal drug candidates, highlighting the importance of the chemical angle in expanding the antifungal therapeutic arsenal. As lipopeptides are amphiphilic middle-size substances and the glucan synthase a complex transmembrane target, many functional details remain to be discovered regarding ECs' modalities of action to circumvent arising resistances. In this pursuit, medicinal chemistry has a significant role to play.
1 December 2011 in Bioorganic & Medicinal Chemistry
We present here the synthetic routes and the experimental data (NMR and MS spectra) for model reactions for copper-free Huisgen 1,4-cycloaddition, Staudinger ligation and for addition of a dithiol on a dibromomaleimide ring. Starting materials were synthesized from the commercially available 4-chlorophenethylamine, previously described 2-(cyclooct-2-yn-1-yloxy)acetic acid, 1-fluorocyclooct-2-ynecarboxylic acid, commercial 2-(diphenylphosphino)terephthalic acid 1-methyl 4-pentafluorophenyl diester and dibromomaleimide. In all cases, the expected compounds were obtained with good yield (50% to quantitative). A novel synthesis of the lipid anchor DOGP3NH2 is also described. These data were used as basis for the study reported in the article "Smart Tools and Orthogonal Click-like Reactions onto Small Unilamellar Vesicles" in Chemistry and Physics of Lipids [1].